Bavarian Nordic has filed a patent for a recombinant Modified Vaccinia Virus Ankara (MVA) that encodes a spike protein of SARS-CoV-2, the virus responsible for COVID-19. The patent claims that the MVA includes a modification that stabilizes the spike protein in a prefusion conformation. GlobalData’s report on Bavarian Nordic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Bavarian Nordic, Recombinant viral vaccines was a key innovation area identified from patents. Bavarian Nordic's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
Recombinant modified vaccinia virus ankara encoding covid-19 spike protein
A recently filed patent (Publication Number: US20230233670A1) describes a recombinant Modified Vaccinia Virus Ankara (MVA) that has been modified to encode the spike (S) full-length protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The modification in the amino acid sequence of the S protein stabilizes it in a prefusion conformation, which is important for its function. This recombinant MVA is capable of inducing an immune response against the SARS-CoV-2 S protein, specifically an antigen-specific T cell response, antigen binding antibodies, and an antigen-specific B cell response.
The patent also describes specific modifications in the amino acid sequence of the SARS-CoV-2 S protein. These modifications include the introduction of two consecutive non-native proline residues at amino acid positions 986 and 987, as well as additional modifications that contribute to stabilizing the S protein in a prefusion conformation. Furthermore, the amino acid sequence of the S protein includes a substitution of consecutive amino acids RRAR with GSAS at a furin cleavage site.
The patent also covers a plasmid that can be used for the preparation of the recombinant MVA described in the claims. The method for preparing the recombinant MVA involves contacting the plasmid with an MVA for homologous recombination.
Additionally, the patent includes a pharmaceutical composition or vaccine comprising the recombinant MVA, along with a pharmaceutically acceptable carrier or excipient. This composition can be used to induce an immune response to SARS-CoV-2 in a subject. The method for inducing an immune response involves administering the pharmaceutical composition or vaccine to the subject. This immune response can help prevent or treat a viral infection, specifically coronavirus disease 19 (COVID-19).
The patent also suggests the use of a homologous prime-boost vaccination regimen, where a boosting administration of the recombinant MVA is given after an initial administration, to enhance the immune response.
In summary, the patent describes a recombinant MVA that encodes the SARS-CoV-2 S protein and has been modified to stabilize the protein in a prefusion conformation. This modified MVA is capable of inducing various immune responses, including T cell responses, antigen binding antibodies, and B cell responses. The patent also covers the plasmid and method for preparing the recombinant MVA, as well as the use of a pharmaceutical composition or vaccine comprising the recombinant MVA to induce an immune response against SARS-CoV-2.
To know more about GlobalData’s detailed insights on Bavarian Nordic, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
